The Role of Interleukin-15 Polymorphisms in Adult Acute Lymphoblastic Leukemia by Lin, Dandan et al.

















1Laboratory of Cellular and Molecular Tumor Immunology, Cyrus Tang Hematology Center, Department of Hematology, Jiangsu Institute of Hematology, The First
Affiliated Hospital, Soochow University, Suzhou, China, 2Thrombosis and Hemostasis Key Lab of the Ministry of Health, Soochow University, Suzhou, China, 3Deparment
of Biochemistry and Molecular Biology, Medical College of Soochow University, Suzhou, China, 4Laboratory of Cancer Molecular Genetics, Medical College of Soochow
University, Suzhou, Jiangsu, China, 5The People’s Hospital of Bozhou, Bozhou, China
Abstract
Background: Interleukin-15 (IL-15) plays important roles in the immune system and in the development of hematopoietic
cells. Previous studies revealed that five SNPs in IL-15, rs10519612, rs10519613, rs35964658, rs17007695 and rs17015014,
were significantly associated with childhood Acute Lymphoblastic Leukemia (ALL) treatment response. In adult ALL, the
expression of IL-15 was also correlated with the immunophenotypes of ALL. Therefore, we hypothesize that SNPs of IL-15
might also be associated with adult ALL.
Methods and Findings: We genotyped the above five SNPs of IL-15 gene by PCR-RFLP assays in adult ALL case-control
studies. The current study included 121 adult ALL patients and 263 healthy controls. IL-15 genotypes and haplotypes were
determined and the associations with the risk of ALL were analyzed by logistic regression. SNPs rs10519612 and rs17007695
were significantly associated with ALL (P=0.013 and P=0.001). We observed a 2-fold and 2.4-fold excess risk of developing
ALL for the rs10519612 CC and rs17007695 TC genotype carriers compared with non-carriers, respectively. Haplotype
analysis revealed that haplotypes ACAC, CAGT and CCAT were significantly associated with adult B-ALL, while haplotype
CCAT conferred susceptibility to T-ALL.
Conclusion: These findings suggest that IL-15 gene polymorphisms are significantly associated with ALL in adult Chinese
population.
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Introduction
The characteristic of acute lymphoblastic leukemia (ALL) is the
clonal proliferation and accumulation of immature lymphoid cells
[1]. Although 80% of children with ALL are cured with
contemporary treatments, many patients still develop serious
acute and late complications owing to the side effects of the
treatments [2,3]. Furthermore, the survival rate for adults with
ALL remains below 40% [4–9]. The relatively poor outcome in
adult ALL has been explained by an increased frequency of high-
risk molecular subtypes with more aggressive clinical behavior and
greater drug resistance, poorer tolerance and compliance with
treatment, and less effective treatment regimens compared with
childhood ALL [6,8,9]. Now many of techniques are used in
diagnosing the biological and clinical differences of leukemic cells,
including the acquisition of new chromosomal abnormalities, gene
mutations, and reduced responsiveness to chemotherapeutic
agents [10–13]. DNA copy number abnormalities (CNAs) and
loss of heterozygosity (LOH) in cancer can be genome-wide
analyzed by Single Nucleotide Polymorphism (SNP) arrays, which
has provided important insights into the pathogenesis of newly
diagnosed ALL [14].
Interleukin-15 (IL-15) was found to share many biological
activities with IL-2, which is a pleiotropic cytokine of the 4-a-helix
bundle cytokine family [15,16]. IL-15 has many functions in
immune system, including the activation of the proliferation and
differentiation of natural killer (NK), T, and B cells, as well as the
maintenance of memory T cells [15–20]. IL-15 appears to play a
major role in the hematopoietic development controlling the
survival, proliferation, and differentiation of both normal and
leukemic progenitors, and can promote pathogenesis of leukemic
cells [21–25]. Some studies have demonstrated that IL-15 can
promote tumor cell growth, expansion, and organ infiltration of
malignancies [23–27]. With respect to the potential clinical and
therapeutic relevance of IL-15 in hematopoietic malignancies,
high levels of IL-15 affect the initial response to therapy and have
a relationship with malignant transformation, including organ
infiltration and disease progression [26–30]. Five SNPs in IL-15
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13626gene identified by genome-wide scan significantly associated with
childhood ALL treatment response [31]. So, IL-15 may play an
important role in the development and progression of ALL.
Because of the possible roles of IL-15 in ALL development, we
performed case–control studies to investigate the association
between the five SNPs in human IL-15 gene and adult ALL
susceptibility in a Chinese population.
Materials and Methods
Study Population
The study group consisted of 121 Han Chinese patients with
ALL, whose age ranged from 20 to 75. The group included 41 T-
ALL patients and 80 B-ALL patients. These patients were
recruited from March 2003 to May 2008 at the First Affiliated
Hospital of Soochow University (Suzhou, China). Diagnosing ALL
began with a medical history and physical examination, complete
blood count and blood smears. Pathological examination,
cytogenetics and immunophenotyping established whether the
blast cells began from the B or T lymphocytes. All eligible patients
diagnosed at the hospital during the study period were recruited,
with a response rate of 94%. Population controls were cancer-free
people living in the same region; they were selected from a
nutritional survey conducted in the same period as the cases were
collected. All control subjects had no history of cancer, and their
age and gender frequency were matched to cases. The clinical
characteristics of patients with acute lymphoblastic leukemia are
shown in Table 1[32].
Ethics Statement
The bone marrow samples of patients and blood samples of
healthy individuals used in this study were part of the samples
taken for clinical diagnostic tests. Since no extra amount of
samples were collected from the study subjects, verbal consent was
received from all patients and healthy control individuals. The
study procedure was approved by the ethics committee of
Soochow University.
DNA extraction and genotyping analysis
Genomic DNA was extracted from 2 ml frozen whole blood or
bone marrow using the RelaxGene Blood DNA system according
to the manufacturer’s protocol (Tiangen, China). A polymerase
chain reaction-restriction fragment length polymorphism (PCR-
RFLP) assay was used to detect polymorphisms. The sequences of
the primers (Shenggong, China) for the PCR and annealing
temperatures for the PCRs are listed in Table 2.
The polymorphic region was amplified by PCR in a 25 ml
reaction solution containing 50 to 100 ng genomic DNA, 16Taq
PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 5 U Taq DNA
polymerase (Fermentas, EU) and 0.2 uM of each primer. PCR
products were digested 3 hrs with restriction enzymes (Takara,
Japan) according to the manufacturer’s protocol and analyzed by
3% agarose gel electrophoresis. The length of PCR products and
restriction enzymes are shown in Table 2.
Statistical analysis
SNP allele frequencies were tested against departure from
Hardy-Weinberg equilibrium (HWE) before analysis. x
2 tests and
independent-samples t test were used to compare the difference in
gender and age between cases and controls. Comparisons of the
distributions of the allele, genotype and haplotype frequencies
were performed using the x
2 test. The relative risk associated with
rare alleles was estimated as an odds ratio (OR) with a 95%
confidence interval (CI). The P values of OR and 95% CI
indicated in the text are used to estimate the significance of the
contribution of corresponding genotype to disease risk. The P
values of genotypes indicated in the tables are used to estimate the
significance of the distribution of genotype between cases and
controls. A P value less than 0.05 was considered statistically
significant. The statistical software package SPSS v. 17.0 was used
for analyses. Haplotype frequencies for pairs of alleles as well as
Linkage Disequilibrium (LD) coefficients D’=D/Dmax and r
2
values for pairs of the most common alleles at each locus were
estimated using the SHEsis program (http://analysis.bio-x.cn/
myAnalysis.php)[33,34].
Results
rs10519612 and rs17007695 of IL-15 gene were
significantly associated with adult ALL
There was no statistical difference in the age and gender
distribution between ALL patients and controls (P=0.381,
P=0.111). The allele and genotype distributions for five SNPs of
IL-15 among cases and controls were summarized in Table 3. The
genotype frequencies of these polymorphisms were in Hardy-
Weinberg equilibrium (P.0.05) in controls in this study. When the
genotype frequencies were compared between cases and controls,
rs10519612 and rs17007695 of IL-15 gene showed statistically
significant association with the disease. The distribution of






















MLL rearrangement 10 8.3
No common translocations 87 71.9
Prognosis Risk Rank
*
Low risk 8 6.6
Intermediate risk 57 47.1
High risk 56 46.3
*According to the risk stratification of adult ALL proposed by Hoelzer et al[32].
doi:10.1371/journal.pone.0013626.t001
IL-15 SNPs and Adult ALL
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13626rs10519612 and rs17007695 genotypes were significantly different
between cases and controls (P=0.013; P=0.001) and the
rs10519612 CC genotype and the rs17007695 TC genotype were
more prevalent among the patients. Increased risks for ALL were
found for the homozygous variant CC (OR 1.96, 95%CI 1.06–
3.61) and TC (OR 2.38, 95%CI 1.43–3.97). The rs10519612 C
allele and rs17007695 C allele carrier frequencies were higher in
patients than in controls (P=0.042, OR 1.37, 95%CI 1.01–1.87;
P=0.041, OR 1.38, 95%CI 1.01–1.88).
We further classified the study subjects into T-ALL and B-ALL
(Table 3). The rs10519612 C allele carrier frequency was higher in
the T-ALL patients than in controls (P=0.030, OR 1.67, 95%CI
1.05–2.67). The rs10519612 CC genotype and the rs17007695
TC genotype frequencies were higher in patients with T-ALL than
in controls (P=0.039, OR 2.68, 95%CI 1.05–6.83; P=0.049, OR
2.28, 95%CI 1.01–5.17). The distribution of rs10519612 and
rs17007695 genotypes were significantly different between B-ALL
patients and controls (P=0.049; P=0.003), while only the
distribution of rs10519612, but not rs17007695 genotypes were
different between T-ALL patients and controls (P=0.041;
P=0.095). An increased risk for B-ALL was found for the
rs17007695 TC genotype (P=0.004, OR 2.40, 95%CI 1.32–4.36).
We also studied whether the IL-15 SNPs were different in BCR-
ABL B-ALL patients and other B-ALL patients (Table S1). Only
the distribution of rs17007695 genotypes in BCR-ABL B-ALL
patients (P=0.004) and rs10519612 genotypes in other B-ALL
patients (P=0.041) was significantly different from the controls.
Increased risks were found for the rs17007695 TC genotype both
in BCR-ABL patients (OR 4.35, 95%CI 1.22–15.55) and other B-
ALL patients (OR 1.99, 95%CI 1.03–3.85).
Haplotypes ACAC, CAGT and CCAT were significantly
associated with adult ALL (especially B-ALL), while
haplotype CCAT conferred susceptibility to T-ALL
D’ and r
2 for these five polymorphisms were calculated
according to the genotyping data reported in Table 3 and
Table 4. Their LD maps measured by D’ and r
2 in cases and
controls were shown in Figure 1. 5-SNP haplotypes were
reconstructed according to the genotyping data in cases and
controls. The frequencies of haplotypes ACACC, CAGCG and
CCATG were higher in ALL patients (OR 2.93, 95%CI 1.26–
6.82, P=0.010; OR 2.17, 95%CI 1.15–4.11, P=0.016; OR 5.27,
95%CI 1.71–16.26, P=0.001). When the patients were further
classified into T-ALL and B-ALL, the frequencies of haplotypes
ACACC and CAGCG were also higher in B-ALL patients (OR
2.89, 95%CI 1.12–7.46, P=0.023; OR 2.09, 95%CI 1.00–4.34,
P=0.046) and the frequency of haplotype CCATG was
significantly higher in T-ALL patients compared with controls
(OR 8.67, 95%CI 2.34–32.11, P,0.001) (Table S2).
Four polymorphisms consisting of rs10519612, rs10519613,
rs35964658 and rs17007695 were in a LD block. Accordingly, 4-
SNP haplotypes (rs10519612, rs10519613, rs35964658 and
rs17007695) were reconstructed according to the genotyping data
in ALL patients and controls. Haplotypes with frequencies $5%
were shown in Table 4. The four common haplotype alleles
represented 89.8% of the chromosomes in the controls. The most
frequent haplotypes observed in patients and controls were
haplotype ACAT (40.2%, 53.2%) and CAGC (31.2%, 29.2%).
The frequencies of haplotypes ACAC, CAGT and CCAT were
significantly higher in ALL patients compared with healthy
controls (OR 3.33, 95%CI 1.57–7.08, P=0.001; OR 2.61,
95%CI 1.30–5.23, P=0.005; OR 7.00, 95%CI 2.40–20.38,
P,0.001). When the data were analyzed separately, the
frequencies of haplotypes ACAC, CAGT and CCAT were only
significantly higher in B-ALL patients compared with healthy
controls (OR 3.75, 95%CI 1.66–8.49, P=0.001; OR 2.99, 95%CI
1.41–6.38, P=0.003; OR 5.25, 95%CI 1.55–17.74, P=0.003).
However, carriage of the CCAT haplotype conferred a 9-fold
higher susceptibility to T-ALL (OR 8.75, 95%CI 2.40–31.86,
P,0.001).
Discussion
IL-15 is a proinflammatory cytokine that promotes the
proliferation of T, B and NK cells and induction of cytolytic
effector cells [27,35,36]. It plays an important role not only in
immune system but also in the growth and survival of immature
hematopoietic cells [21–23], which could be the reason for its role
in pathogenesis of leukemic cells [24,25]. Some studies have
already demonstrated that IL-15 can protect hematologic tumors
from drug induced apoptosis in vitro [25], and high expression of
IL-15 correlates with CNS disease in childhood ALL [26]. Several
IL-15 SNPs which were associated with minimal residual disease
(MRD) have been linked to enhanced IL-15 transcription/
translation efficiency in vitro [37]. Five SNPs located in the IL-15
Table 2. Primers and Restriction Endonucleases used for genotyping IL-15 gene.
SNP ID Primer sequences Product Annealing Restriction
Length (bp) temperature(uC) Endonucleases
rs10519612 F: 59-CTCAATGTCCTTAACCCATTATTCGA-39 137 56.1 BspT104 I
R: 59-CGTTTGAACCATATGGTGAGGTCT-39
rs10519613 F: 59-TAGACATAACAAAACACTCGGCATTT-39 122 59.3 Dra I
R: 59-CTCAATGACATTTTTCTGCCTTCA-39
rs35964658 F: 59-GTTCTGAAACTTTTCATCAAATGAGC-39 149 62.4 Hha I
R: 59-CTAGCCTTACTGGGGAAAATGG-39
rs17007695 F: 59-GTCTTTCTCATGGTCCTCATTGA-39 126 56.1 BspT104 I
R: 59-AAAATTTACAAATGTGTGATTTTCGA-39
rs17015014 F: 59-CGGACTGCTGGGTCTAAGAAGCTA-39 119 62.4 Xsp I
R: 59-GTCTGACTCATCAGCCAACACCC-39
F=Forward Primer; R=Reverse Primer.
doi:10.1371/journal.pone.0013626.t002
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childhood ALL treatment response. Therefore, IL-15 plays a role
in treatment response in childhood ALL [31]. In adult ALL, the
expression of IL-15 was correlated with the immunophenotypes of
ALL, patients with T-ALL and B-cell precursor (BCP)-ALL have
different expression levels of IL-15 [38]. In the current study, we
identified two SNPs (rs10519612, rs17007695) that were associ-
ated with the risk for adult ALL. In the haplotype analysis, we
further concluded that haplotypes ACAC, CAGT and CCAT
were significantly associated with adult ALL (especially B-ALL),
while haplotype CCAT conferred susceptibility to T-ALL.
When we evaluated each of the selected SNPs’ genotypes
separately, the rs10519612 CC genotype and rs17007695 TC
genotype were found to be associated with the increased risk; the
other SNPs had no significant correlation with the risk for adult
ALL. We demonstrated that the presence of the rs10519612 CC
genotype and the rs17007695 TC genotype increased the risk of
ALL about two folds. When T-ALL and B-ALL were analyzed
separately, rs10519612 CC genotype and the rs17007695 TC
genotype conferred risk for T-ALL (2.68 fold and 2.28 fold
increase), while only the rs17007695 TC genotype was associated
with B-ALL (2.4 fold increase). In B-ALL study, the distribution of
rs10519612 CC and rs17007695 TC genotypes were different
compared with controls, while only the distribution of rs10519612
CC genotypes were different in T-ALL.
Although five SNPs have been reported to be associated with
childhood ALL treatment response [31], we only found two of
them correlated with adult ALL in the present study. Out of total
121 ALL patients recruited in this study, 48 were treated relatively
uniformly with induction regimen. Among those, 34 achieved CR
(T-ALL 5, B-ALL 29), 4 achieved PR (T-ALL 3, B-ALL 1), and
ten of them were not responding (NR, T-ALL 8, B-ALL 2). We
performed association studies of the SNPs of IL-15 gene with the
treatment responses, and none of them was significantly associated
Table 3. Genotype and allele frequencies of IL-15 SNPs among ALL cases and controls and associations with risk of ALL.
SNP ALL Subjects (Cases/controls) T-ALL Subjects (Cases/controls) B-ALL Subjects (Cases/controls)
n (%) OR (95% CI)
* P n (%) OR (95% CI)
* P n (%) OR (95% CI)
* P
rs10519612
Genotype AA 38/91 (31.4/34.6) 1.00 10/91 (24.4/34.6) 1.00 28/91 (35.0/34.6) 1.00
AC 51/135 (42.1/51.3) 0.88 (0.53–1.45) 19/135 (46.3/51.3) 1.25 (0.55–2.84) 32/135 (40.0/51.3) 0.74 (0.42–1.32)
CC 32/37 (26.4/14.1) 1.96 (1.06–3.61)
& 0.013 12/37 (29.3/14.1) 2.68 (1.05–6.83)
& 0.041 20/37 (25.0/14.1) 1.62 (0.81–3.26) 0.049
Allele A 127/317 (52.5/60.3) 1.00 39/317 (47.6/60.3) 1.00 88/317 (55.0/60.3) 1.00
C 115/209 (47.5/39.7) 1.37 (1.01–1.87) 0.042 43/209 (52.4/39.7) 1.67 (1.05–2.67) 0.030 72/209 (45.0/39.7) 1.24 (0.87–1.77) 0.236
rs10519613
Genotype CC 40/103 (33.1/39.2) 1.00 12/103 (29.3/39.2) 1.00 28/103 (35.0/39.2) 1.00
CA 62/131 (51.2/49.8) 1.17 (0.73–1.89) 23/131 (56.1/49.8) 1.46 (0.69–3.10) 39/131 (48.7/49.8) 1.05 (0.60–1.83)
AA 19/29 (15.7/11.0) 1.56 (0.78–3.11) 0.315 6/29 (14.6/11.0) 1.48 (0.50–4.40) 0.450 13/29 (16.3/11.0) 1.49 (0.68–3.28) 0.436
Allele C 142/337 (58.7/64.1) 1.00 47/337 (57.3/64.1) 1.00 95/337 (59.4/64.1) 1.00
A 100/189 (41.3/35.9) 1.26 (0.92–1.72) 0.152 35/189 (42.7/35.9) 1.33 (0.83–2.13) 0.238 65/189 (40.6/35.9) 1.22 (0.85–1.75) 0.282
rs35964658
Genotype AA 31/85 (26.1/32.3) 1.00 10/85 (24.4/32.3) 1.00 21/85 (26.9/32.3) 1.00
AG 67/142 (56.3/54.0) 1.25 (0.76–2.08) 26/142 (63.4/54.0) 1.48 (0.68–3.25) 41/142 (52.6/54.0) 1.12 (0.62–2.02)
GG 21/36 (17.6/13.7) 1.52 (0.77–3.00) 0.368 5/36 (12.2/13.7) 1.09 (0.34–3.44) 0.511 16/36 (20.5/13.7) 1.69 (0.79–3.64) 0.298
Allele A 129/312 (54.2/59.3) 1.00 46/312 (56.1/59.3) 1.00 83/312 (53.2/59.3) 1.00
G 109/214 (45.8/40.7) 1.23 (0.91–1.68) 0.185 36/214 (43.9/40.7) 1.14 (0.71–1.83) 0.582 73/214 (46.8/40.7) 1.28 (0.90–1.84) 0.175
rs17007695
Genotype TT 27/104 (22.3/39.5) 1.00 9/104 (22.0/39.5) 1.00 18/104 (22.5/39.5) 1.00
TC 80/124 (66.1/47.1) 2.38 (1.43–3.97)
& 25/124 (61.0/47.1) 2.28 (1.01–5.17)
& 55/124 (68.8/47.1) 2.40 (1.32–4.36)
&
CC 14/35 (11.6/13.3) 1.40 (0.65–3.01) 0.001 7/35 (17.1/13.3) 2.19 (0.74–6.47) 0.095 7/35 (8.7/13.3) 1.02 (0.39–2.69) 0.003
Allele T 134/332 (55.4/63.1) 1.00 43/332 (52.4/63.1) 1.00 91/332 (56.9/63.1) 1.00
C 108/194 (44.6/36.9) 1.38 (1.01–1.88) 0.041 39/194 (47.6/36.9) 1.55 (0.97–2.48) 0.064 69/194 (43.1/36.9) 1.30 (0.91–1.86) 0.155
rs17015014
Genotype GG 30/75 (24.8/28.5) 1.00 9/75 (22.0/28.5) 1.00 21/75 (26.3/28.5) 1.00
GC 67/133 (55.4/50.6) 1.22 (0.73–2.05) 24/133 (58.5/50.6) 1.43 (0.63–3.27) 43/133 (53.7/50.6) 1.12 (0.62–2.03)
CC 24/55 (19.8/20.9) 1.07 (0.56–2.03) 0.659 8/55 (19.5/20.9) 1.20 (0.43–3.36) 0.600 16/55 (20.0/20.9) 1.03 (0.49–2.17) 0.879
Allele G 127/283 (52.5/53.8) 1.00 42/283 (51.2/53.8) 1.00 85/283 (53.1/53.8) 1.00
C 115/243 (47.5/46.2) 1.06 (0.78–1.43) 0.733 40/243 (48.8/46.2) 1.11 (0.70–1.77) 0.663 75/243 (46.9/46.2) 1.03 (0.72–1.47) 0.880
*Adjusted for age and gender status.
&P,0.05.
P for Chi-square analysis or Fisher’s exact test.
doi:10.1371/journal.pone.0013626.t003
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association of these SNPs with the disease prognosis and treatment
responses, which would be extremely meaningful in future studies.
The combined analysis of SNPs in IL-15 and other genes may also
be needed since the polymorphisms in IL-15 might not serve as a
sole risk factor for the disease prognosis. Moreover, our study may
have certain limitations because of the study design. Selection bias
and/or systematic error may occur because the cases were from
Figure 1. LD maps of the five SNPs of IL-15. LD maps of the five SNPs of IL-15 for ALL cases and controls were generated by SHEsis program. For
each SNP, D’ and pair r
2 values were shown in diamonds in two groups, including ALL patients and healthy controls.
doi:10.1371/journal.pone.0013626.g001
Table 4. Haplotype frequencies of IL-15 in ALL cases and controls
*.
Haplotype{ All Subjects T-ALL Subjects B-ALL Subjects
Frequencies
1 OR(95%CI) P Frequencies
1 OR(95%CI) P Frequencies
1 OR(95%CI) P
A C A T 40.2/53.2 1.00 39.3/53.2 1.00 40.9/53.2 1.00
A C A C 6.7/2.7 3.33 (1.57–7.08) 0.001 5.4/2.7 2.50 (0.78–8.05) 0.113 7.5/2.7 3.75 (1.66–8.49) 0.001
C A G C 31.2/29.2 1.40 (0.98–2.01) 0.067 34.4/29.2 1.59 (0.92–2.74) 0.092 29.9/29.2 1.34 (0.87–2.04) 0.181
C A G T 7.2/3.7 2.61 (1.30–5.23) 0.005 4.4/3.7 1.84 (0.59–5.75) 0.286 8.4/3.7 2.99 (1.41–6.38) 0.003
C C A T 4.9/1.0 7.00 (2.40–20.38) ,0.001 6.2/1.0 8.75 (2.40–31.86) ,0.001 4.1/1.0 5.25 (1.55–17.74) 0.003
*Haplotypes with frequencies of more than 5% were included.
{Four SNPs alleles from left to right (rs10519612, rs10519613, rs35964658 and rs17007695) were used for reconstruction of haplotypes.
1Haplotype frequencies (%) in patients and healthy controls.
doi:10.1371/journal.pone.0013626.t004
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which may interact with genotype or act as potential confounders
in analysis such as information of MRD is not available in our
case-control studies.
In the present study, we demonstrated that the polymorphisms
of IL-15 genes were associated with adult ALL. Although whether
the SNPs that were significantly associated with the disease are
functional needs to be further investigated, our results presented
here clearly suggested that IL-15 play a role for in the
tumorigenesis of adult ALL and may lead to the perspective for
IL-15 as a novel therapeutic target in adult ALL.
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ALL cases and controls and associations with risk of ALL.
Found at: doi:10.1371/journal.pone.0013626.s001 (0.09 MB
DOC)
Table S2 Haplotype frequencies of IL-15 in ALL cases and
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